Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2026)

Recursion Pharmaceuticals (RXRX) has 5 years of Cost of Revenue data on file, last reported at $12.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 42.78% year-over-year to $12.5 million; the trailing twelve-month figure through Mar 2026 stood at $61.6 million (up 10.22% YoY), and the FY2025 full-year result was $71.0 million, up 56.84% from the prior year.
• Cost of Revenue for Q1 2026 stood at $12.5 million, down from $14.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $21.8 million in Q1 2025 and bottomed at $7.8 million in Q1 2022.
• The 5-year median for Cost of Revenue is $12.4 million (2023), against an average of $12.9 million.
• The widest annual swing landed in 2025, when Cost of Revenue jumped 119.17%; it then plunged 42.78% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $10.8 million in 2022, then retreated by 8.85% to $9.9 million in 2023, then grew by 29.48% to $12.8 million in 2024, then rose by 11.58% to $14.3 million in 2025, then retreated by 12.5% to $12.5 million in 2026.
• The last three Cost of Revenue figures came in at $12.5 million (Q1 2026), $14.3 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.

Peer Comparison